EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects

Virendra Rambiritch, Poobalan Naidoo, Goonaseelan Pillai

Clinical Pharmacology: Advances and Applications · 2016

DOI: 10.2147/cpaa.s102674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2016. Verfasst von Virendra Rambiritch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, University of KwaZulu-Natal, Durban. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Nonmemdose–response relationshipsglibenclamidepharmacokinetic/pharmacodynamic modelingtype 2 diabetes

Autor:innen und Institutionen

  • Pharmacology Department, University of KwaZulu-Natal, Durban.
  • Department of Internal Medicine, RK Khan Regional Hospital, Chatsworth, South Africa.
  • Scientific Capability Development, Novartis Pharma AG, Basel, Switzerland.

Zitieren

APA

Rambiritch, V., Naidoo, P., & Pillai, G. (2016). Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects. Clinical Pharmacology: Advances and Applications. https://doi.org/10.2147/cpaa.s102674

Vancouver

Rambiritch V, Naidoo P, Pillai G. Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects. Clinical Pharmacology: Advances and Applications. 2016. doi:10.2147/cpaa.s102674

BibTeX
@article{Rambiritch2016,
  author = {Rambiritch, Virendra and Naidoo, Poobalan and Pillai, Goonaseelan},
  title = {Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects},
  journal = {Clinical Pharmacology: Advances and Applications},
  year = {2016},
  doi = {10.2147/cpaa.s102674}
}
Kostenlos starten →